Dcf Advisers, LLC Impel Pharmaceuticals Inc Transaction History

Dcf Advisers, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.31 - $1.75 $38,782 - $218,933	-125,105 Reduced 41.21%	178,500 $76,000
Q2 2023 Aug 09, 2023	SELL	$1.08 - $2.75 $85,906 - $218,743	-79,543 Reduced 20.76%	303,605 $385,000
Q1 2023 May 15, 2023	BUY	$0.96 - $4.1 $55,030 - $235,024	57,323 Added 17.59%	383,148 $536,000
Q4 2022 Feb 13, 2023	SELL	$2.59 - $4.0 $371,297 - $573,432	-143,358 Reduced 30.55%	325,825 $1.22 Million
Q3 2022 Nov 14, 2022	BUY	$5.78 - $9.32 $176,966 - $285,350	30,617 Added 6.98%	469,183 $2.29 Million
Q2 2022 Aug 11, 2022	BUY	$5.83 - $10.12 $416,891 - $723,660	71,508 Added 19.48%	438,566 $4.09 Million
Q1 2022 May 13, 2022	BUY	$5.86 - $9.85 $650,641 - $1.09 Million	111,031 Added 43.37%	367,058 $2.34 Million
Q4 2021 Feb 10, 2022	BUY	$8.33 - $12.14 $883,204 - $1.29 Million	106,027 Added 70.68%	256,027 $2.21 Million
Q3 2021 Nov 15, 2021	BUY	$8.38 - $26.13 $1.26 Million - $3.92 Million	150,000 New	150,000 $1.83 Million

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.